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Introduction 
According to the Prohibited List of the World Anti-Doping Agency (WADA), the use of any 
unapproved drug for human therapeutic use is strictly prohibited in sports. [1] 
The use of performance-enhancing peptides is a growing issue in human [2-5] as well as equine 
sports drug testing. [6] 
A product called TB-500, claimed to increase muscle growth and tissue repair in horses and 
other mammals, is available on the internet and officially distributed. It is presented as “the 
synthetic peptide of the active region of thymosin beta 4 (Tβ4)”, without any further 
qualitative description such as amino acid sequence or molecular weight. Tβ4, a 43 amino 
acid peptide, is the most abundant member of beta thymosins. [7] Its primary function is to 
stimulate the production of T cells, which are an important part of the immune system. 
Additionally, Tβ4 has been shown to prevent apoptosis, promote cell survival, angiogenesis, 
and tissue regeneration in mice and rats. [8] 
TB-500 is intended for veterinary use only (10 mg/dose), but it is legit to suspect its use as 
doping agent not only in horse and greyhound racing, but even in humans. Indeed, TB-500 
packages, containing 6 powder vials and physiological saline solutions for injection, were 
already confiscated by legal officials declaring that the product was for personal use. In at 
least one case this received also world-wide attention from the media since it was connected 
to a former professional athlete which was still employed by his team, [9] while in another 
case, a former team doctor was arrested in the possession of the substance. [10] These events 
suggest that TB-500 might also be used by athletes for doping purposes, although no evidence 
for a misuse has been reported so far. 
A preventive and proactive approach against these novel formulations containing peptidic 
drugs without any clinical approval is mandatory, including identification of the active 
content of these products, in order to monitor its misuse. Additionally, methods need to be 
developed for their detection and preferably, well characterized reference standards need to be 
synthetized. The aim of this work was therefore to identify, to synthesize and suggest an 
analytical strategy to detect the active compound in plasma and urine.  
Materials and methods 
Chemicals and reagents 
All the reagents were analytical or HPLC grade. Reference standard of human Tβ4 was 
purchased from Bachem (Weil am Rhein, Germany). 
Acetonitrile, water, dichloromethane were purchased from BioSolve (Lexington MA, USA). 
Glacial acetic acid was purchased from Merck (Darmstadt, Germany); Methanol, formic acid, 
N,N'-diisopropylcarbodiimide (DIC), 4-dimethylaminopyridine (DMAP), N,N-
diisopropylethylamine (DIPEA), piperidine, pyridine, (methyl-t-butyl ether (MTBE), and 
acetic anhydride were purchased from Sigma-Aldrich (S. Louis, USA). 
All the fluorenylmethyloxycarbonyl chloride (Fmoc) protected amino acids were L-isomers. 
Fmoc-Lys(Boc)OH, Fmoc-Thr(tBu)OH, Fmoc-Glu(tBu)OH were purchased from Nova 
Biochem (San Diego, CA, USA). Fmoc-Leu-OH precoated WANG-Resin was purchased 
from Bachem. Fmoc-Gln(Trt)OH and O-benzotriazole-N,N,N’,N’-tetramethyl-uronium-
hexafluoro-phosphate (HBTU) from Iris Biotech GnBH (Marktredwitz, Germany). 
TB-500 
A TB-500 package, confiscated by Belgian Customs during a routine control, was delivered to 
the laboratory. The sealed vial contained approximately 10 mg of a white powder. Stock (1 
mg/mL) and working solutions (100 µg/mL and 100 ng/mL) of TB-500 and human Tβ4 from 
lyophilized powders were prepared by dissolving them in aqueous acetic acid (2% v/v). 
Liquid chromatography 
Chromatographic separation was achieved with a Surveyor MS Pump Plus coupled with a 
Surveyor Plus autosampler (Thermo Scientific, Bremen, Germany) using a Zorbax RX-C8 
reverse-phase column (2.1 x 150 mm, 5 µm) from Agilent Technologies (Santa Clara, USA). 
The conditions were the same for both high-resolution and low-resolution MS experiments. 
For each sample, 5 µL were injected. A binary gradient was used: mobile phase A consisted 
of water containing 0.2% formic acid; mobile phase B consisted of acetonitrile containing 
0.2% formic acid. Gradient elution was as follows: it started from 100% A for 5 minutes, then 
decreased linearly to 0% A in 10 minutes, and held at 0% A for 2 minutes. Finally, 95% A 
was eluted for 3 minutes to equilibrate the system for further injection experiments, for a total 
run time of 20 minutes. A constant flow rate of 300 µl/min was maintained. 
Mass spectrometry 
High-resolution mass spectrometry (HRMS) experiments were performed on an Exactive 
benchtop, Orbitrap-based mass spectrometer (Thermo Scientific, Bremen, Germany). The 
instrument operated both in positive full scan MS mode and positive higher-energy collision 
dissociation (HCD) “all ion fragmentation” MS/MS mode at 25 eV. The sheath gas (nitrogen) 
pressure was set to 60 (arbitrary units), the auxiliary gas (nitrogen) pressure set to 30 
(arbitrary units) and the capillary temperature set to 350°C. The capillary voltage and spray 
voltage were set to 30 V and 3 kV, respectively. The instrument operated in full scan mode 
from m/z 100–2000 at 100,000 resolving power. The data acquisition rate was 1 Hz. 
Approximately 10 scans were averaged per spectrum. 
Low-resolution MS/MS characterization of TB-500 was performed on a TSQ Quantum 
Discovery Triple Stage Quadrupole Mass Spectrometer (Thermo Scientific, Bremen, 
Germany) equipped with an ESI source operating in positive mode The ESI–MS operating 
variables used in this study were as follows: capillary voltage, 3.5 kV; source temperature, 
350 °C; sheath gas (nitrogen) pressure, 30 psi; auxiliary gas (nitrogen) pressure, 10 psi; tube 
lens offset, 84V. 
Data analysis 
ProMass software from Thermo Fisher (Bremen, Germany) was used for spectral 
deconvolution. Protein Prospector v 5.8.0 (http://prospector.ucsf.edu/prospector) was used to 
compare and match acquired HCD spectra to those predicted in silico. Mass tolerance was set 
at 5 ppm. 
Synthesis of the peptide 
Ac-Tβ4(17-23) was synthesized using a standard Fmoc-SPS protocol. [11] The C-terminal 
amino acid (FmocGln(Trt)OH) was already coupled to WANG-resin with 0.63 mmol/g 
loading. Subsequent coupling of amino acids was achieved using 3eq amino acid, 3eq HBTU 
as activator and 6eq DIPEA as base in DMF. After each coupling, including the coupling to 
WANG-resin the protective Fmoc group was removed with 20% (v/v) piperidine in DMF. 
Acetylation of the N-terminus was achieved with 1M acetic anhydride in pyridine. The 
peptide was cleaved from the resin using Reagent K [12] and precipitated in MTBE. 
Analysis of spiked plasma and urine  
2 ml of blank plasma and 2 ml of blank urine were spiked with the peptide at 500 pg/ml. 2 ml 
of saturated ammonium sulfate (Merck, Darmstadt, Germany) solution were added to plasma 
and the samples were centrifuged (4100 g, 1 h, 2°C) to precipitate plasma proteins. Both 
plasma and urine were then acidified with 50 µl of 10% formic acid and processed by solid-
phase extraction (SPE) using Oasis MCX (60 mg) cartridges, purchased from Waters 
(Milford, USA). The column was first activated with 2 ml of methanol and subsequently 
rinsed with 2 ml of 5% acetic acid. After the sample was loaded, the column was washed first 
with 2 ml of 5% acetic acid, then with 2 ml of methanol. Finally, samples were eluted with 
1.25 ml of a solution consisting of 80:20 methanol:5% ammonia. The eluate was evaporated 
to dryness with a centrifugal evaporator (45°C, 240 g), and then dissolved in 100 µl of 95:5 
water:acetonitrile, containing 0.1% formic acid.
Results 
HRMS identification of the active content of TB-500 
Solutions of TB-500 were first injected for HPLC-HRMS analysis in order to identify the 
active ingredient(s) in the formulation. Total ion chromatogram showed one main peak, which 
could be assigned to originate from a peptide-like structure at tr= 9.1 min. The full scan MS 
spectrum (data not shown) revealed the presence of two molecular ions of the same molecule, 
respectively 445.2532 ([M+2H]2+) and 889.4988 ([M+H]+). Spectrum deconvolution provided 
a molecular weight (MW) of 888.4910. It was immediately evident that TB-500 did not 
contain the endogenous Tβ4 (MW: 4963.4642). Therefore, elucidation of the structure of the 
detected species was accomplished by de novo sequencing based on HCD of the peptide 
precursor at 25 eV. b+ and y+ ions allowed de novo sequencing of the peptide through direct 
matching with theoretical data. As shown in Figure 1(a) and summarized in Table 1, a 
heptapeptide was detected, corresponding to the 17-23 fragment of human Tβ4 (sequence: 
LKKTETQ). Additionally, all b+ ions showed a positive m/z shift of 42.0105 with respect to 
the Tβ4 fragment, indicating the presence of an acetylated N-terminus. The identified peptide 
(theoretical MW 888.4911) will be further referred to as Ac-Tβ4(17-23). Finally, a 
confirmation of the structure was given after synthesis of the peptide, as shown by the  HCD 
spectrum depicted in Figure 1(c), by comparison of respective NMR spectra in Figure 1(b) 
and 1(d), and the chromatograms in Figure 2. When a gradient with a slower increase was 
used for TB-500 (0% to 20% B in 10 minutes instead of 0% to 100% B) to check for the 
presence of coeluting substances or stereoisomeric impurities still a single peak was observed 
(data not shown). No other active substances or excipients were detected during the analysis.    
Low-resolution MS/MS of Ac-Tβ4(17-23) 
Low resolution MS/MS data can provide useful information to monitor in a sensitive way the 
presence of these substances by selected reaction monitoring (SRM). 
The product ion scan spectrum (20 eV) of Ac-Tβ4(17-23) of the parent ion [M+2H]2+ at m/z 
445.5 shows an elevated number of fragments, including the complete y and b ion series and 
several internal fragments. These results are depicted in Figure 3. Additionally, Table 2 shows 
the results from optimization of MS parameters for the SRM detection of the compound. The 
product ions at m/z 84.1 and 129.1, related to the glutamine and lysine residues were the most 
abundant. 
 
Discussion 
TB-500 is one of several formulations available on the online market that contain a peptidic 
drug which is claimed to enhance sport performances. Although it is marketed only for 
veterinary use it is sold to non-veterinarians as well via the internet and there is anecdotal 
evidence that is probably used by athletes. In the last years, several research groups have 
investigated and highlighted the increasing problem of the use of non-approved designer 
peptides[2-5], which were often only identified after the products had been confiscated by 
Custom Police officers.  
Ac-Tβ4(17-23) corresponds to the acetyl derivative of the major actin-binding site of Tβ4, 
that has been shown to promote angiogenesis, wound healing and hair growth in vitro and in 
animal models. [13] Therefore, the plausible rationale for use of TB-500 in doping lies in the 
role of Ac-Tβ4(17-23) in tissue growth and regeneration, which can be particularly important 
for recovery after intense workout or competition. The non-acetylated form of the peptide has 
been detected in vivo as an endogenous degradation product of Tβ4, [13] whereas the 
acetylated form is not described. N-terminal acetylation is a common strategy in drug 
development of peptides to increase the half-life, and therefore the activity, of peptides. [14] 
This acetylation should  allow for a clear differentiation between endogenous and exogenous 
Tβ4 in biological samples, although metabolic deacetylation should be investigated.The 
absence of reference standards for most of the black market peptides, including Ac-Tβ4(17-
23), presents a problem in doping control concerning the fulfillment of compound 
identification criteria. Moreover, some of these products contain different ingredients as 
officially claimed in the product description These differences include amino acid 
substitution, truncation, or other chemical modifications. Additionally, due to the lack of 
information on pharmacokinetic properties of this peptide and the ethical impossibility to 
administer these unknown preparations to healthy volunteers, its urinary or serum detection 
can generally only be postulated. Due to its relatively low molecular weight, renal excretion 
could be expected, with sub-nanogram urinary concentration similarly to other oligopeptides 
[15,16]
 but this educated guess needs to be confirmed experimentally.  However, in order to 
provide useful indication for the detection of the intact peptide, urine samples were spiked 
with Ac-Tβ4(17-23) and processed by protein precipitation (only for plasma samples) and 
solid-phase extraction (SPE) before LC-MS analysis. Figure 4 shows the detection of Ac-
Tβ4(17-23) both in urine and plasma  spiked at a concentration of 0.5 ng, using product ions 
at m/z 129.0 and 606.4 from precursor ion at m/z 445.5. Awaiting more pharmacokinetical 
information from approved administration studies to humans or, taking into account the 
ethical aspects more likely, other species, the authors suggest to monitor misuse of this 
peptide in plasma and/or urine with these protocols. 
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Figure captions 
Figure 1 
HCD MS/MS recorded at 20 eV (a) and 700 MHz-NMR (b) spectra of TB-500. The structure 
of the peptide was confirmed after synthesis of the Ac-Tβ4(17-23), which presents identical 
MS/MS (c) and NMR (d) spectra. 
Figure 2 
TIC and base peak chromatogram for TB-500 (a, b), the synthesized Ac-Tβ4(17-23) (c, d), 
and Tβ4 (e, f). 
Figure 3 
Full scan MSMS spectrum of Ac-Tβ4(17-23) at 20eV. 
Figure 4 
Detection of Ac-Tβ4(17-23) in plasma (b) and urine (d) after fortification with 0.5 ng of 
peptide. The peptide was not detected in blank plasma (a) or in blank urine (c). 
Table captions 
Table 1 
Identification of Ac-Tβ4(17-23) based on matching between the experimental and in silico 
data on b ions from HCD experiments. 
Table 2 
Main results from MSMS optimization of Ac-Tβ4(17-23) from TB-500. 
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